A Randomized, Double-Masked, Single-Center, Placebo-Controlled Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of SJP-0132 in Subjects With Dry Eye Disease
Latest Information Update: 24 Apr 2023
At a glance
- Drugs SJP 0132 (Primary)
- Indications Dry eyes
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Senju Pharmaceutical
Most Recent Events
- 01 Mar 2021 Allocation changed from single group assignment to parallel.
- 16 Mar 2020 Status changed from recruiting to completed.
- 31 Oct 2019 New trial record